Investing in Johnson & Johnson
Johnson & Johnson has been a part of people's lives for 129 years and a valuable part of their investments for approximately 70 years. Founded in 1886, we listed our shares on the New York Stock Exchange for public investors in 1944.
During our history, we have built the most comprehensive base of health care businesses in the world, generating approximately 70 percent of our revenues from No. 1 or No. 2 global leadership positions in our respective markets.
Our consistent performance has enabled us to deliver an exceptional track record of growth that few, if any, companies can claim: 31 consecutive years of adjusted earnings increases and 52 consecutive years of dividend increases. Over the last 10 years, Johnson & Johnson stock generated a 8.3 percent total return for investors compared to a 7.7 percent total return for the S&P 500.(1)
March 30, 2015
New Study Shows Reduced Hospital Admissions and Costs for Deep Vein Thrombosis Patients Treated with XARELTO® Compared to Traditional Therapy, With No Difference in Subsequent Hospital Visits
March 29, 2015
New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia
March 27, 2015
Johnson & Johnson to Webcast Annual Meeting of Shareholders
April 23, 2015 at 10:30 AM ET
Johnson & Johnson Annual Meeting of Shareholders
April 14, 2015 at 8:30 AM ET
Johnson & Johnson First Quarter 2015 Earnings Call and Webcast
Financial Quick Links
1. Data source - Bloomberg